Arcus Biosciences logo

Arcus Biosciences

RCUS | NYSE
Chart Builder DCF Calculator
$16.86
-$0.57 (-3.27%)
At close: Nov 16, 2026, 4:00 PM ET
$16.86
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:01 PM ET
-3.27%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
33.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #707/1021 (Top 69%)

Key Statistics

Market Data

Market Cap $2.43B
1D Range
16.76 17.74
52W Range
16.76 31.57

Valuation (TTM)

PE -4.61
PB 6.78
EV/EBITDA -4.61

Valuation (NTM)

Forward PE N/A
Forward PEG -2.65
Price Target $42.50
Loading financial charts...

Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan,...

Sector Healthcare
Industry Biotechnology
Employees 601
IPO Date Mar 14, 2018
Fiscal Year January - December

Latest News

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates

12 days ago · zacks.com

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates
Arcus Biosciences Announces New Employment Inducement Grants

21 days ago · businesswire.com

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

26 days ago · businesswire.com

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences Announces Commencement of Public Offering of Common Stock

26 days ago · businesswire.com

Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead

27 days ago · seekingalpha.com

Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript

27 days ago · seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

28 days ago · zacks.com

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

2 months ago · businesswire.com

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

2 months ago · seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Earnings

Latest Earnings
Nov 4, 2026
EPS
-$1
Miss -12.26%
REV
$9M
Beat +18.72%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$42.50
Upside
+152.08%
Buy (6)
Hold (3)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.